{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:52:59Z","timestamp":1795024379556,"version":"4.10.2"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Whether glycemic control, as opposed to diabetes status, is associated with the severity of NAFLD is open for study. We aimed to evaluate whether degree of glycemic control in the years preceding liver biopsy predicts the histological severity of NASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>\n                      Using the Duke NAFLD Clinical Database, we examined patients with biopsy\u2010proven NAFLD\/NASH (n\u00a0=\u00a0713) and the association of liver injury with glycemic control as measured by hemoglobin A1c (HbA1c). The study cohort was predominantly female (59%) and White (84%) with median (interquartile range) age of 50 (42, 58) years; 49% had diabetes (n\u00a0=\u00a0348). Generalized linear regression models adjusted for age, sex, race, diabetes, body mass index, and hyperlipidemia were used to assess the association between mean HbA1c over the year preceding liver biopsy and severity of histological features of NAFLD\/NASH. Histological features were graded and staged according to the NASH Clinical Research Network system. Group\u2010based trajectory analysis was used to examine patients with at least three HbA1c (n\u00a0=\u00a0298) measures over 5\u00a0years preceding clinically indicated liver biopsy. Higher mean HbA1c was associated with higher grade of steatosis and ballooned hepatocytes, but not lobular inflammation. Every 1% increase in mean HbA1c was associated with 15% higher odds of increased fibrosis stage (OR, 1.15; 95% CI, 1.01, 1.31). As compared with good glycemic control, moderate control was significantly associated with increased severity of ballooned hepatocytes (OR, 1.74; 95% CI, 1.01, 3.01;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.048) and hepatic fibrosis (HF; OR, 4.59; 95% CI, 2.33, 9.06;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&lt;\u00a00.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Glycemic control predicts severity of ballooned hepatocytes and HF in NAFLD\/NASH, and thus optimizing glycemic control may be a means of modifying risk of NASH\u2010related fibrosis progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.31806","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T09:20:36Z","timestamp":1615886436000},"page":"1220-1233","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":137,"title":["Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease"],"prefix":"10.1097","volume":"74","author":[{"given":"Anastasia\u2010Stefania","family":"Alexopoulos","sequence":"first","affiliation":[{"name":"Division of Endocrinology,Department of Medicine,Duke University,Durham,,NC"},{"name":"Durham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT),Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Crowley","sequence":"additional","affiliation":[{"name":"Division of Endocrinology,Department of Medicine,Duke University,Durham,,NC"},{"name":"Durham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT),Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Department of Medicine,Duke University,Durham,,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Moylan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Department of Medicine,Duke University,Durham,,NC"},{"name":"Division of Gastroenterology,Durham Veterans Affairs Medical Center,Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia D.","family":"Guy","sequence":"additional","affiliation":[{"name":"Department of Pathology,Duke University,Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Henao","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics,Duke University,Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Piercy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Department of Medicine,Duke University,Durham,,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-0786","authenticated-orcid":false,"given":"Keri A.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Division of Metabolic Surgery,Department of Surgery,Duke University,Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Sudan","sequence":"additional","affiliation":[{"name":"Division of Metabolic Surgery,Department of Surgery,Duke University,Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana D.","family":"Portenier","sequence":"additional","affiliation":[{"name":"Division of Metabolic Surgery,Department of Surgery,Duke University,Durham,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mae","family":"Diehl","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Department of Medicine,Duke University,Durham,,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea D.","family":"Coviello","sequence":"additional","affiliation":[{"name":"Division of Endocrinology,Department of Medicine,Duke University,Durham,,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-8618","authenticated-orcid":false,"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Department of Medicine,Duke University,Durham,,NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"hep31806-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep31806-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31806-bib-0003-20250824","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta\u2010analysis","volume":"96","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"hep31806-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non\u2010alcoholic fatty liver disease","volume":"65","year":"2016","journal-title":"Metabolism"},{"key":"hep31806-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep31806-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31806-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00535-018-1468-9","article-title":"Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non\u2010alcoholic fatty liver disease","volume":"53","year":"2018","journal-title":"J Gastroenterol"},{"key":"hep31806-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep4.1054","article-title":"Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease","volume":"1","year":"2017","journal-title":"Hepatol Commun"},{"key":"hep31806-bib-0009-20250824","article-title":"Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta\u2010analysis","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"hep31806-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta\u2010analysis of cohort studies","volume":"130","year":"2012","journal-title":"Int J Cancer"},{"key":"hep31806-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ecl.2016.06.005","article-title":"Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus","volume":"45","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"hep31806-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all\u2010cause mortality and liver\u2010related mortality in patients with non\u2010alcoholic fatty liver disease (NAFLD)","volume":"58","year":"2013","journal-title":"Dig Dis Sci"},{"key":"hep31806-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"hep31806-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","year":"2004","journal-title":"Hepatology"},{"key":"hep31806-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep31806-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group\u2010based trajectory modeling in clinical research","volume":"6","year":"2010","journal-title":"Annu Rev Clin Psychol"},{"key":"hep31806-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0049124101029003005","article-title":"A SAS procedure based on mixture models for estimating developmental trajectories","volume":"29","year":"2001","journal-title":"Sociol Methods Res"},{"key":"hep31806-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of follow\u2010up biopsies reveals disease progression in patients with non\u2010alcoholic fatty liver","volume":"59","year":"2013","journal-title":"J Hepatol."},{"key":"hep31806-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/dc09-0148","article-title":"Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"key":"hep31806-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00535-013-0911-1","article-title":"Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients","volume":"49","year":"2014","journal-title":"J Gastroenterol"},{"key":"hep31806-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing\u2010steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep31806-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/hep.23784","article-title":"Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"hep31806-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clinre.2018.08.007","article-title":"Association of glycated hemoglobin with the risk of advanced fibrosis in non\u2010alcoholic fatty liver disease patients without diabetes","volume":"43","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"hep31806-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/hepr.13282","article-title":"Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non\u2010alcoholic fatty liver disease","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep31806-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510290347","article-title":"Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease","volume":"29","year":"1999","journal-title":"Hepatology"},{"key":"hep31806-bib-0029-20250824","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00535-004-1475-x","article-title":"Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt\u2010out NASH","volume":"39","year":"2004","journal-title":"J Gastroenterol"},{"key":"hep31806-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box!","volume":"101","year":"2019","journal-title":"Metabolism"},{"key":"hep31806-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"hep31806-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/L16-0628","article-title":"Long\u2010term pioglitazone treatment for patients with nonalcoholic steatohepatitis","volume":"166","year":"2017","journal-title":"Ann Intern Med"},{"key":"hep31806-bib-0033-20250824","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non\u2010alcoholic steatohepatitis (LEAN): a multicentre, double\u2010blind, randomised, placebo\u2010controlled phase 2 study","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"hep31806-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo\u2010controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"hep31806-bib-0035-20250824","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/hep.22724","article-title":"Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD\u2010Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"hep31806-bib-0036-20250824","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30418","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials","volume":"70","year":"2019","journal-title":"Hepatology"},{"key":"hep31806-bib-0037-20250824","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1210\/clinem\/dgaa112","article-title":"Glycemic measures and development and resolution of nonalcoholic fatty liver disease in nondiabetic individuals","volume":"105","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 1","key":"hep31806-bib-0038-20250824","first-page":"S34","article-title":"4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"hep31806-bib-0039-20250824","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","year":"2019","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31806","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:12:46Z","timestamp":1756077166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31806","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"2020-09-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}